Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Elanco Animal Health Incorporated (ELAN) vs United Therapeutics Corporation (UTHR)

Elanco Animal Health Incorporated and United Therapeutics Corporation are both Drug Manufacturers Specialty & Generic companies. United Therapeutics Corporation is the larger, with a market value of $20.3B against $11.2B — 1.8× the size. Elanco Animal Health Incorporated has negative trailing earnings, so its P/E is not meaningful; United Therapeutics Corporation trades at 15.7×. Elanco Animal Health Incorporated grew revenue faster over the last twelve months: 12.0% against 2.49%. United Therapeutics Corporation has the higher net margin (41.6% vs −3.96%) and the higher return on invested capital (23.4% vs 0.51%). Across the 21 metrics below, United Therapeutics Corporation leads on 17 and Elanco Animal Health Incorporated on 4.

Valuation

Metric ELAN UTHR Drug Manufacturers Specialty & Generic median
P/E n/m 15.70 20.14
P/S 2.22 6.42 2.25
P/B 1.69 3.16 1.90
Price to free cash flow 31.22 18.62 16.54
EV/EBITDA 18.78 11.98 12.29
EV/Sales 2.89 5.67 2.56
Earnings yield (1.84%) 6.37% (2.99%)
Free cash flow yield 3.20% 5.37% 0.00%

Profitability

Metric ELAN UTHR Drug Manufacturers Specialty & Generic median
Gross margin 55.36% 86.14% 53.94%
Operating margin 1.61% 44.44% 0.00%
Net margin (3.96%) 41.56% 0.00%
Free cash flow margin 7.55% 34.65% 0.00%
Return on equity (2.98%) 19.32% (0.40%)
Return on assets (1.46%) 17.33% (3.32%)
Return on invested capital 0.51% 23.44% 0.00%

Growth

Metric ELAN UTHR Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 11.95% 2.49% 10.01%
EPS growth (last fiscal year) (169.12%) 13.07% —
Revenue growth, 5-year CAGR 7.59% 16.50% 6.74%
Net income growth, 5-year CAGR 0.00% 20.99% 0.00%

Health

Metric ELAN UTHR Drug Manufacturers Specialty & Generic median
Debt to equity 0.59 0.00 0.05
Current ratio 2.05 5.73 2.31
Net debt to EBITDA 5.00 (1.85) 0.85

Dividend

Metric ELAN UTHR Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric ELAN UTHR Drug Manufacturers Specialty & Generic median
Market cap 11.21b 20.25b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack